Given the role of MMP9 in mobilization of hematopoietic stem and (endothelial) progenitor cells, our findings confirm NO levels in the BM as a potential modifiable upstream target to promote E(PC) mobilization in cardiovascular disease. This evidence concerns the gene MMP9 and cardiovascular disorder.